The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Clinical trial NCT02595983 · COMPLETED

Trial details

NCT number: NCT02595983
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Transthyretin (TTR)-Mediated Amyloidosis Familial Amyloidotic Polyneuropathy (FAP)ATTR Amyloidosis Familial Amyloid Neuropathies

Start date: 2015-10-01
Primary completion: 2017-02-06
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.